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tinin. We found that 47% and 39% of the patients had 
positive test results for aprotinin-specific IgG antibodies 
early and late after exposition. Not much is known about 
the precise immunologic sequel during an adverse reac- 
tion to aprotinin. Determination of aprotinin-specific IgG 
antibodies might be a useful clinical indicator to identify 
individuals at risk for anaphylactic reactions to aprotinin, 
but more precise methods are desirable. 
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PRIMARY TRACHEAL SYNOVIAL CELL SARCOMA: A FIRST CASE REPORT 
Anne T. Sykes, MD, a Chris K. Rokkas, MD, ~ Andre Kajdacsy-Balla, MD, b and George B. Haasler, MD," 
Milwaukee, Wis. 
Synovial cell sarcoma is a rare soft-tissue tumor com- 
prising only 7% of all soft-tissue sarcomas, with fewer than 
10% of those involving the head and neck. It has never 
been described involving the trachea as the primary site. 
We report here a case of primary tracheal synovial cell 
sarcoma nd review the limited data available on diagno- 
sis, prognosis, and treatment of this tumor. 
Clinical summary. A 20-year-old white male college 
student with a 3-year history of exercise-induced asthma 
was being treated with bronchodilators. Progressive dys- 
pnea, stridor, intermittent hemoptysis, and a 15 kg weight 
loss developed over a 3-month period. Coughing episodes 
elicited anterior chest pain radiating to the back. An 
episode of respiratory distress prompted a visit to the 
emergency department. Results of physical examination 
were remarkable for respiratory stridor and wheezing. 
The patient continued to have symptoms despite systemic 
steroid therapy. Bronchoscopy revealed a smooth, pale, 
soft tracheal tumor extending proximally to 3 cm below 
the true vocal cords, occupying most of the tracheal 
lumen. Computed tomography demonstrated a 3 cm 
intratracheal mass extending outside the tracheal wall, 
with its distal extension 5 cm above the carina (Fig. 1). 
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There was neither clinical nor radiographic evidence of 
lymphadenopathy. 
The patient underwent en bloc tumor excision with 
tracheal resection by a neck approach through a low collar 
incision. Intraoperative bronchoscopy revealed a normal 
distal tracheobronchial tree. Five tracheal rings with clear 
surgical margins of at least 1 cm were removed, and 
primary end-to-end anastomosis was performed. Grossly, 
the mass appeared well circumscribed, with transmural 
extension into the paratracheal region but without gross 
invasion into fat. The patient recovered uneventfully and 
was discharged to home on the fourth postoperative day 
without bronchodilators. Results of metastatic workup, 
including computed tomography of the chest, abdomen, 
and pelvis and a bone scan, were negative. He was 
referred to radiation oncology and received a total of 62 
Gy external beam irradiation in 22 fractions of 180 cGy 
and boost therapy in 12 fractions of 180 cGy. He has not 
been treated with adjuvant chemotherapy. The patient 
remains well 8 months after the operation. 
Pathology. Histologically, the tumor showed biphasic 
growth. The pattern was composed mostly of ill-defined 
interweaving fascicles of monomorphic spindle cells but 
also showed numerous clear-cut foci of cuboidal cells 
forming pseudoglandular dusters (Fig. 2, a). This biphasic 
pattern was even more obvious when immunohisto- 
chemical stains were used to show mutually exclusive 
vimentin-positive spindle cells and the epithelial com- 
ponent positive for low-molecular weight cytokeratin 
and carcinoembryonic antigen (Fig. 2, b). Numerous 
scattered mast cells were seen. Both components of the 
tumor stained negative for intracellular mucin (Alcian 
blue at pH 2.5, periodic aeid-Sehiff, and mucicarmine), 
argyrophilic granules (Grimelius stain), and immuno- 
histochemically for chromogranin, S-100, B72.3, 
smooth-muscle actin, and desmin. 
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Fig. 1. Computed tomography demonstrates tracheal mass nearly obstructing lumen. Note extension 
outside normal umen. Artifact caused by humeral heads. Each unit on the scale at the right represents 1 
cm. R, Right; L, left. 
Fig. 2. Biphasic growth pattern characteristic of synovial cell sarcoma, a, Epithelial cell nests within sheets 
of spindle cells (Hematoxylin-eosinophil stain; ×500). b, Spindle and epithelial cell structures confirmed 
with immunohistochemical st ining (high-molecular weight cytokeratin stain; >(500). 
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Discussion. Synovial cell sarcoma is an exceedingly 
rare tumor in the head and neck, Jernstrom 1 described the 
first synovial cell sarcoma of the head and neck in 1954. 
Fewer than 50 cases have been reported since, and fewer 
than 10% of these have involved the larynx or hypophar- 
ynx. They are commonly seen as large, painless neck 
masses in young men. Encroachment on adjacent struc- 
tures may result in dysphagia, hoarseness, or airway 
obstruction. These symptoms often arise late and portend 
a poorer prognosis. 
When occurring in the head and neck, synovial cell 
sarcomas are thought o arise from pleuripotential stem 
cells without any association with a synovial structure. 
They spread by way of direct extension along muscular 
and fascial planes and are rarely associated with nodal 
metastasis. 2 Pulmonary metastatic disease has been de- 
scribed in some 40% of patients with head and neck 
synovial cell sarcomas, a mean of 30.8 months after 
resection. 3 Although no studies have definitively demon- 
strated tumor size or histologic grade as prognostic fac- 
tors, delay in diagnosis and narrow surgical margins have 
been shown to worsen outcome. 3 
The histologic diagnosis of synovial cell sarcoma is 
according to the classic biphasic histologic pattern of 
spindle cells mixed with glandular and epithelial elements, 
along with positive immunohistochemical staining for 
vimentin and cytokeratin. Other tumors, such as malig- 
nant fibrous histiocytoma, carcinoid, rhabdomyosarcoma, 
mesothelioma, pulmonary blastoma, and malignant glan- 
dular schwannoma, constitute the differential diagnosis 
and in our patient were ruled out by clinical, morphologic, 
and immunohistochemical differences. 
Optimal treatment for head and neck synovial cell 
sarcomas is wide surgical excision of the tumor without 
lymphadenectomyfl' 3 There are no data supporting the 
use of adjuvant chemotherapy. Radiation therapy has 
been shown to improve local control of head and neck 
synovial cell sarcomas if given in doses greater than 50 
Gy. 3 
Our patient's tumor was diagnosed late despite the fact 
that he had respiratory symptoms of 3 years' duration. His 
physical and radiographic examinations have ruled out 
another primary tumor and have excluded metastatic 
disease to date. With local recurrences of head and neck 
synovial cell sarcomas and metastases occurring as late as 
62 months after surgical resection, 2  3 long-term follow-up 
with computed tomography of the neck and chest is 
probably indicated. This patient will be followed up with 
bronchoscopy and computed tomography of the neck and 
chest every 6 months for a minimum of 5 years. 
REFERENCES 
1. Jernstrom P. Synovial sarcoma of the pharynx: report of a 
case. Am J Clin Pathol 1954;24:957-6 I. 
2. Roth JA, Euzinger FM, Tannengaum M. Synovial sarcoma of 
the neck: a foltowup study of 24 cases. Cancer 1975;35:1243-53, 
3. Amble FR, Olsen KD, Nascimento AG, Foote RL. Head and 
neck synovial cell sarcoma. Otolaryngol Head Neck Surg 
1992;107:631-7. 
IMMOBILIZED INSTRUMENT FOR MINIMALLY INVASIVE DIRECT CORONARY ARTERY 
BYPASS: MIDCAB DOUGHNUT 
Masao Takahashi, MD, Shinichiro Yamamoto, MD, and Shigeki Tabata, MD, Fukui, Japan 
So that satisfactory vessel immobilization can be 
achieved, enabling consistently accurate grafting during 
off-pump coronary artery bypass grafting (CABG), me- 
chanical immobilizing devices 1-3 have been developed 
along with immobilization methods including pharma- 
cologic control of heart rate to produce bradycardia 2 
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and induction of transient ventricular asystole with 
adenosine. Even with heart rates of about 40 beats/rain, 
however, the technical demands of suturing are often 
difficult. In this report, we describe a new immobilizing 
instrument for use during minimally invasive CABG on 
the beating heart. With this instrument, a motionless 
and bloodless operative field can be achieved without 
occlusion of the distal coronary artery. The use of this 
instrument facilitates the new techniques of operating 
on the beating heart. 
Techniques. The instrument, called a MIDCAB dough- 
nut, consists of a double-bottomed silicone rubber dome 
and a suction tube that is supported with a handle. It 
has a simple structure, and its elastic firm material is 
thought o be safe and secure. The elastic dome has a 
small hole (14 to 16 mm in diameter) at the center 
through which the coronary artery that is being anasto- 
mosed can be positioned. The dimensions of the dome 
